News
Clarametyx Biosciences Awarded $2.7 Million in Option Funding From CARB-X to Accelerate Novel Technology for Persistent Bacterial Infections
Award expands development resources following completion of $8 million…
Clarametyx Biosciences Expands Board of Directors with Appointment of Financial Executive Michael Layman
Mr. Layman joins as an independent director as the company continues to…
Clarametyx featured in 2021 Technology Showcase, hosted by Nationwide Children’s Hospital’s Office of Technology Commercialization
Clarametyx Chief Scientific Officer Chuck McOsker participated in the 2021 NCH…
David Richards Appointed CEO of Clarametyx Biosciences
Company also expands Board of Directors with the appointment of Larry Edwards…
Newly Published Insights in Biofilm Illustrate the Powerful Mechanisms of an Antibody Biofilm Eradication Therapy Approach
Biofilms represent a substantial challenge to treating bacterial infections,…
Clarametyx Biosciences Awarded Up to $14.2 Million From Carb-x to Accelerate Novel Immune-enabling Technology to Combat Persistent Bacterial Infections
Funding agreement fuels development of platform targeting universal structure…
Data Published in Ebiomedicine Validates Novel Scientific Approach that Disarms Bacterial Defenses to Treat or Prevent Life-threatening Infections
Approach effectively degrades bacterial protective shields to enable immune or…
Clarametyx Biosciences Launches with an Ambitious Strategy to Address Life-threatening Bacterial Infections
Renowned Columbus-based leaders and scientific innovators to develop novel…